| |
| |
|
| Insider
Information: |
Rodino-Klapac Louise |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
68,073 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$8,765,760 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
68,073 |
|
|
| Total
Value |
$8,765,760 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Sarepta Therapeutics Inc |
SRPT |
|
2024-03-08 |
68,073 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
19 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SRPT |
Sarepta Therapeutics Inc |
Head of R&D, CSO |
• – – |
2024-03-08 |
4 |
D |
$123.14 |
$111,934 |
D/D |
(909) |
68,073 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Head of R&D, CSO |
• – – |
2024-03-07 |
4 |
D |
$120.49 |
$61,691 |
D/D |
(512) |
68,982 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Head of R&D, CSO |
• – – |
2024-03-04 |
4 |
D |
$125.32 |
$216,553 |
D/D |
(1,728) |
69,494 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Head of R&D, CSO |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
71,222 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Head of R&D, CSO |
• – – |
2024-03-01 |
4 |
D |
$126.19 |
$98,176 |
D/D |
(778) |
65,222 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Head of R&D, CSO |
• – – |
2023-11-17 |
4 |
D |
$82.98 |
$374,074 |
D/D |
(4,508) |
65,751 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Head of R&D, CSO |
• – – |
2023-03-08 |
4 |
D |
$153.19 |
$139,709 |
D/D |
(912) |
70,170 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Head of R&D, CSO |
• – – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
71,082 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Head of R&D, CSO |
• – – |
2023-03-06 |
4 |
D |
$157.21 |
$178,276 |
D/D |
(1,134) |
66,582 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Head of R&D, CSO |
• – – |
2023-03-01 |
4 |
D |
$147.57 |
$77,032 |
D/D |
(522) |
67,716 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Head of R&D, CSO |
• – – |
2022-11-17 |
4 |
D |
$108.52 |
$456,978 |
D/D |
(4,211) |
67,998 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Head of R&D, CSO |
• – – |
2022-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
72,111 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Head of R&D, CSO |
• – – |
2022-03-04 |
4 |
D |
$79.20 |
$96,307 |
D/D |
(1,216) |
64,111 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Head of R&D, CSO |
• – – |
2022-03-01 |
4 |
D |
$75.05 |
$42,929 |
D/D |
(572) |
65,327 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Chief Scientific Officer |
• – – |
2021-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
61,898 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Chief Scientific Officer |
• – – |
2021-03-03 |
4/A |
A |
$0.00 |
$0 |
D/D |
15,000 |
21,780 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Chief Scientific Officer |
• – – |
2021-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
22,169 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Chief Scientific Officer |
• – – |
2021-02-28 |
4/A |
D |
$86.97 |
$49,138 |
D/D |
(565) |
6,604 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Chief Scientific OfficerOffice |
• – – |
2020-12-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,169 |
|
% |
|
19 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
